Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos, a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies, has received EUR2.7m from the Flemish agency for Innovation by Science and Technology (IWT) to progress its proprietary antiviral drug discovery research programs.
Subscribe to our email newsletter
The two-year IWT-funded project aims to advance compounds against human rhinovirus (HRV), the virus that causes the common cold and hepatitis C virus (HCV), with the target to bring out a first preclinical candidate within the next one year.
Galapagos will collaborate on this project with the research group of professor Johan Neyts at the Rega Institute for Medical Research at the KU Leuven.
Galapagos SVP of Drug Discovery Graham Dixon said the grant provides funding for them to further understand the mechanism by which these orally available, small molecules play a role in inhibiting viral infection.